On this episode, Dennis Walker talks with Aaron Paul Orsini, the co-founder of Autistic Psychedelic Community, author of Autism on Acid, and producer of the recently released, therapy-friendly instrumental music album “Psychedelic Symphonies."
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
![Is it TOO LATE to buy MindMed? [MMEDF] 🍄](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-151-600x338.jpeg)
MindMed (MMEDF/MMED) stock EXPLODED in the past week which raises the question: Is it too late to BUY MindMed stock? Watch the video as I provide my insight on some factors you might want to consider. 💯
Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.
One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.
So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?
You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com
Timestamps:
0:00 – Intro
1:11 – What is Microdosing & How does it Work?
2:55 – Microdosing Benefits
7:28 – Why Microdosing? ( Regimen & Protocols)
14:12 – Discussing microdosing & placebo effects
19:21 – Personal Microdosing Experiences & Consistency
24:09 – Microdosing Advice for Beginners
#PsychedelicStocks #MindMed #MicrodosingPsilocybin
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
![MindMed Raises $19.5 Million // What Does This Mean for MMEDF/MMED? [Plus Upcoming Market CRASH?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-48-600x338.jpeg)
Hey guys! Today’s episode is more of a fast rant on the recent press release about MindMed raising ANOTHER $19.5M from Canaccord Genuity Corp, on a deal that is set to close tomorrow, March 9th.
Here, I’m discussing:
1. The number MindMed shares being sold and their respective price;
2.Why is MindMed doing this?
3. Potential short term and long term effects on MMED’s stock price
4. Nasdaq uplisting?
5. Market crash thoughts
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
In this episode, we discuss how ketamine therapy can help high-performance professional athletes and corporate executives.
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
